



**FOR IMMEDIATE RELEASE**

**PERRIGO IS NAMED AUTHORIZED GENERIC PARTNER BY FERNDAL  
LABORATORIES AND LAUNCHES ANALPRAM HC® CREAM**

ALLEGAN, Mich.– April 15, 2010 – Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has been named as an authorized generic partner by Ferndale Laboratories and has launched an authorized generic of Analpram HC® Cream. Perrigo will also have the opportunity in the future to launch other Ferndale products as the authorized generic distributor.

Analpram HC® Cream is a topical anesthetic and corticosteroid combination and is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and had sales of approximately \$24 million for the 12 months period prior to generic market formation of last year, as measured by Wolters Kluwer Health.

Perrigo’s Chairman and CEO Joseph C. Papa concluded, “We are excited that Ferndale has chosen Perrigo as their preferred partner for authorized generics. This is another example of our focus on expanding our portfolio of prescription extended topical products. As always, Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders.”

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The Company’s primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (<http://www.perrigo.com>).

*Note:* Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current

expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Arthur J. Shannon, Vice President, Investor Relations and Communication  
(269) 686-1709  
E-mail: [ajshannon@perrigo.com](mailto:ajshannon@perrigo.com)

Daniel B. Willard, Manager, Investor Relations and Communication  
(269) 686-1597  
E-mail: [dbwillard@perrigo.com](mailto:dbwillard@perrigo.com)